ACCORD HEALTHCARE, INC.
ACCORD HEALTHCARE, INC. appears in FDA public data with 94 recalls — including 2 Class I (most serious) —, 0 510(k) clearances, 4 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0656-2026, Class II) was initiated on June 8, 2026.
Summary
- Total Recalls
- 94 (2 Class I)
- 510(k) Clearances
- 0
- Inspections
- 4
- Compliance Actions
- 0
Known Names
accord healthcare, accord healthcare, inc
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0656-2026 | Class II | Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: A | June 8, 2026 |
| D-0006-2026 | Class II | Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured f | September 16, 2025 |
| D-0518-2025 | Class II | Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 90-count bottle, Rx Only, Manufactured for: Ac | June 20, 2025 |
| D-0519-2025 | Class II | Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottle, Rx Only, Manufactured for: | June 20, 2025 |
| D-0522-2025 | Class II | Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 1000-count bottle, Rx Only, Manufactured for: | June 20, 2025 |
| D-0523-2025 | Class II | Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottle, Rx Only, Manufactured for: | June 20, 2025 |
| D-0521-2025 | Class II | Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 1000-count bottle, Rx Only, Manufactured for: A | June 20, 2025 |
| D-0520-2025 | Class II | Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 90-count bottle, Rx Only, Manufactured for: Acc | June 20, 2025 |
| D-0524-2025 | Class II | Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 1000-count bottle, Rx Only, Manufactured for: | June 20, 2025 |
| D-0397-2025 | Class II | Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 90 bottles, Rx Only, Manufactured for Accord | April 10, 2025 |
| D-0394-2025 | Class II | Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000 bottles, Rx Only, Manufactured for Accord | April 10, 2025 |
| D-0396-2025 | Class II | Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000 bottles, Rx Only, Manufactured for Accord | April 10, 2025 |
| D-0395-2025 | Class II | Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000 bottles, Rx Only, Manufactured for Accord | April 10, 2025 |
| D-0076-2025 | Class II | Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: | November 8, 2024 |
| D-0032-2025 | Class II | Cinacalcet Tablets, 90 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-442-10, b) 90 Tablets per b | October 10, 2024 |
| D-0030-2025 | Class II | Cinacalcet Tablets 30 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-440-10, b) 90 Tablets per bo | October 10, 2024 |
| D-0031-2025 | Class II | Cinacalcet Tablets, 60 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-441-10, b) 90 Tablets per b | October 10, 2024 |
| D-0010-2025 | Class II | Cisplatin Injection, 100mg/100mL (1mg/mL), For Intravenous Use, 100 mL Multiple Dose Vial, Rx Only, | October 1, 2024 |
| D-0580-2024 | Class III | Dodex Injectable (Cyanocobalamin Injection) USP, 1,000mcg/mL, 1mL multiple dose vial, Rx only, Manuf | June 18, 2024 |
| D-0918-2023 | Class II | Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare | July 3, 2023 |